copper cu 64-dota-pembrolizumab
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 25, 2023 (NCT05728372)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05728372 | Early Phase 1 (Phase 1) | Aug 25, 2023 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1